ArticleArchives of gynecology and obstetrics2026
Methotrexate in relatively contraindicated ectopic pregnancies: who benefits from treatment?
Article in Archives of gynecology and obstetrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to evaluate the efficacy of methotrexate (MTX) therapy and identify clinical and laboratory predictors of treatment failure, particularly in relatively contraindicated cases. MATERIALS AND
methodsThis retrospective cohort study included 225 hemodynamically stable patients with ectopic pregnancy treated with MTX between January 2019 and December 2024 at a tertiary university hospital. Relatively contraindicated cases were defined as having one or more of the following: β-hCG ≥ 5000 IU/L, ectopic mass ≥ 4 cm, fetal cardiac activity, or pelvic free fluid ≥ 5 cm. 58 patients met these criteria, while 167 were MTX-indicated. All patients received a single-dose intramuscular MTX protocol (50 mg/m
resultsThe overall MTX success rate was 85.8%. Success was significantly higher in the indicated group (92.8%) than in the relatively contraindicated group (65.5%). In the latter, treatment failure was significantly associated with higher baseline β-hCG levels and the pelvic free fluid ≥ 5 cm in the pouch of douglas. Multivariate analysis identified a significant association between these factors and MTX failure (β-hCG: OR 7.44, p < 0.001; free fluid: OR 4.10, p = 0.022). Other parameters, including fetal cardiac activity, yolk sac presence, adnexal mass size, and patient age, did not show a significant relationship in this model. The median time to surgical intervention in failed cases was 7 days.
conclusionSingle-dose MTX remains a safe and effective option for carefully selected patients with relatively contraindicated ectopic pregnancies, achieving a 65.5% success rate. High baseline β-hCG and pelvic free fluid may serve as predictors of treatment failure, but do not preclude medical management when close monitoring is ensured. The proposed scoring system should be considered exploratory and requires external validation before clinical implementation. Further prospective studies are needed to confirm these findings and better define candidates for MTX therapy in high-risk cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.